ainewsblitz.com

Breaking

Genentech Exercises Option on First AI-Discovered Neuroscience Target Under Recursion Pact

Genentech Exercises Option on First AI-Discovered Neuroscience Target Under Recursion Pact
  • Healthcare
  • Research & Papers

Roche and its Genentech unit have advanced the first drug target from their AI-based drug-discovery partnership with Recursion Pharmaceuticals, an early test of whether artificial intelligence can help uncover new medicines in one of biology's hardest fields. The target, tied to an undisclosed neurodegenerative disease, was identified by analyzing Recursion's proprietary datasets and confirmed through extensive laboratory experiments before Genentech exercised a validated-target option.

Continue reading

The rest of this article is for AI News Blitz readers. Choose an option below to keep reading.

$20
Read this article
$29/month
Unlimited — all 27,934 articles, the full archive, and comprehension quizzes
Save 72%
$98/year
≈ $8.17/month
Unlimited, billed once a year